Biosimilars and transparency can tame employers' $80,000-per-year drug bills

By Sharon Faust

Commentary September 29, 2025 at 11:25 AM

Share & Print

What You Need To Know

DMARDs like Humira are grown from living organisms and may cost as much as $80,000 per year.
Biosimilars are clinically equivalent and may cost as little as $15,000 per year.
Price transparency can encourage providers and patients to try the new options.

More From HR Executive

NOT FOR REPRINT

© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.